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We examined possible effects of the state of the dorsal raphe nucleus (DRN) on morphine­
induced antinociception in morphine­tolerated and nontolerated rats. Stereotaxically, 
lidocaine (2%) was applied to the DRN for its reversible inactivation. On the test day, all 
animals received 10 mg/kg morphine 10 min before the tail­flick test (induction of thermal 
acute pain), and the maximum antinociceptive effect (MPE) was measured. In the morphine­
tolerated group, animals preliminarily received everyday introductions of 20 mg/kg morphine 
for four consecutive days. There was a significant increase in the MPE (%) in the lidocaine­
treated group (with inactivation of the DRN) compared to the control group. However, there 
was no significant difference in morphine­induced antinociception between the saline­ and 
lidocaine­treated groups. Nonetheless, the antinociceptive responses to morphine (MPE) in 
morphine­tolerated rats were more significant in animals treated with lidocaine compared 
to the control group. Our results suggest that lack of GABA in the locus coeruleus, which 
follows inhibition of serotonin release in the DRN during ablation, may cause adrenergic cell­
induced analgesic effects.  
Keywords: pain, dorsal raphe nucleus, reversible inactivation, morphine tolerance, 
lidocaine, locus coeruleus.
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INTRODUCTION
In the dorsal raphe nucleus (DRN) localized in the 
ventromedial part of the midbrain periaqueductal gray 
(PAG) [1�, various neurotransmitters, including 5­HT 
(serotonin) and opioids, are released [2, 3�. There is 
much evidence showing that the DRN is involved 
in the mechanisms of pain modulation [4, 5�, and 
serotonergic neurons play a major role in these effects 
[1, 2�. There are many anatomical and functional 
connections between the DRN and other parts of the 
brain [6, 7�. The locus coeruleus (LC) is one of these 
regions connected with the DRN [8, 9�. Kishi et al. 
[4� showed that serotonergic neurons of the DRN and 
noradrenergic neurons of the LC cooperate with each 
other in monoamine­mediated antinociception. The 
DRN exerts a much stronger effect on evoked LC 
activity than on spontaneous activity in this structure; 
this may indicate that serotonin exerts presynaptic 
effects on inbound fibers carrying pain­related 
information [10�. Inhibitory serotonergic synapses 
from the raphe were identified in the LC. The DRN 
potentially provides antagonistic actions on the LC 
responses to noxious stimuli [10�.
Previous studies showed that serotonergic and 
opioidergic neurons are localized in the DRN, and 
several studies have been carried out on interactions 
between these two systems. Serotonin 5­HT
1A
 
receptors regulate the opioid release in the spinal 
cord [11�. The 5­HT
3
 receptors induce the release 
of opioid peptides that could inhibit the release of 
neurotransmitters regulating the sympathetic tonus and 
blood pressure [12�. Opioids may mediate behavioral 
templates induced by incitement of brain 5­HT
2 
receptors [13, 14�. Some changes should happen in 
DRN cellular activity after morphine administration 
due to a possible feedback loop if morphine acts 
presynaptically on serotonergic synapses [15�. 
Morphine analgesia decreases in patients who received 
repeated administration of this agent [16�. Also, the 
above two systems collaborate with the involvement 
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of adrenergic neurons, i.e., the opioidergic and 
noradrenergic systems intensely interact with each 
other [17�. In particular, these systems interact 
significantly when providing intense analgesia at the 
spinal level [18�. 
As is known, noradrenergic cells form seven groups 
in the brain (A1­A7) [19�, and one of these groups 
(A6) is located in the LC [17�. This group is connected 
with some other brain nuclei related to pain behaviors. 
The PAG also sends a lot of information to this region 
[20�. 
There is evidence that the DRN is responsible for 
antinociceptive effects. It was shown that post­ictal 
analgesia decreased under conditions of neurotoxic 
lesion of the DRN [2�. In another investigation, 
stimulation of the DRN and some part of the PAG could 
induce analgesic effects [21�. At the same time, Segal 
[10� established that the DRN could exert nociceptive 
effects by inhibitory influences on the LC. According 
to Wang and Nakai [1�, the DRN is considered a 
nucleus having strong descending and ascending pain 
inhibitory pathways. The DRN serotonergic activity 
can be decreased by constant administration of 
morphine (according to [22�). 8­OH­DPAT, an agonist 
of 5­HT
1A
 receptors, inhibited morphine­induced 
tolerance to antinociception influences [23�. There are 
indications that apoptosis increased in the DRN in the 
case of long­lasting exposure to morphine [24, 25�. 
Thus, there are controversial  ideas on the 
mechanisms responsible for DRN involvement in 
morphine­induced tolerance to pain. This is why we 
tried to examine the effects of reversible inactivation 
of the DRN on pain modulation in morphine­tolerant 
and nontolerant experimental animals.
METHODS
Animals and Drugs. Adult male albino Wistar 
rats (body mass 230­280 g) were used in our 
experiments. Animals were housed under standard 
vivarium conditions in groups of three per cage 
at a constant temperature of 22 ± 2°C with a 
12/12­h light/dark cycle (lights on at 7:00 a.m.).
Morphine sulfate (Temad, Iran), 2­(diethylamino)­
N­(2,6­dimethylphenyl) acetamide, and lidocaine 
(Iran) were dissolved in sterile saline (0.9%). Control 
animals received normal saline as a vehicle.
Stereotaxic Surgery. All surgical procedures 
were conducted under ketamine/xylazine (100 mg/kg 
ketamine + 10 mg/kg xylazine, i. p.) anesthesia. 
Stainless steel 23­gauge guide cannulae were 
stereotaxically (Stoelting, USA) implanted in the 
DRN considering the following coordinates: AP = 
= 7.8 mm caudal to bregma, Lat = 0.00, DV= 4.5 mm 
ventral from the skull surface [26� The cannulae 
were 11 mm long, and their tips were 1 mm above 
the appropriate injection place. Jeweler screws and 
dental acrylic cement were applied for securing 
the cannulae. After the cement was completely 
hardened, two stainless steel stylets occluded the 
guide cannulae during the recovery period. Animals 
were individually housed and allowed to recover 
for 5­7 days before the experiments. The injection 
volume was 0.5 µl in each side and injection lasted 
1 min. The needle was left in place for another 
60 sec before they were slowly withdrawn. In sham­
operated group, animals received no injections.
Tail-Flick Test. A standard tail­flick analgesiometer 
apparatus was used for testing the acute thermal 
pain (IR ray heating). The baseline of the tail­flick 
latency (TFL) was within a 3­4 sec range, caused by 
manually setting of the light intensity at about 35% of 
the maximum. The equipment was calibrated in order 
to obtain two consecutive baseline TFLs between 3 
and 4 sec. The cut­off point was determined as 10 sec 
to prevent tissue damage [27�. The TFLs (sec) were 
expressed either as raw data or as a percentage of the 
maximal possible effect (MPE) calculated from the 
following formula:
MPE =
post­drug latency (sec) – baseline latency (sec)
·100%
cut­off value (sec) – baseline latency (sec)
 Experimental Design. A 2% lidocaine solution 
was bilaterally administered to the DRN for reversible 
inactivation of this area. The control group received 
saline instead of lidocaine. The tail­flick test was 
performed to measure the intensity of acute pain 15, 
30, 45, and 60 min after administrations. 
For estimation of morphine­induced analgesia, 
morphine (10 mg/kg) was subcutaneously (s.c.) 
injected 10 min before the tail­flick test. The MPE 
values were calculated for both control and lidocaine­
treated groups.
To clarify the effects of DRN inactivation on 
morphine­tolerated rats, such animals received 4 
everyday introductions of 20 mg/kg morphine during 
four days. The day dose was divided into two equal 
(10 mg/kg) doses, which were injected at 8 a.m. and 
6 p.m. On the test day, lidocaine was administered to 
inactivate the DRN [28�. The control group received 
saline instead of lidocaine. A test dose of 10 mg/kg 
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morphine was injected, and 10 min later the tail flick 
test was performed. The MPEs were calculated for 
both control and lidocaine­treated groups.
Histological Verification. At the end of each 
experiment, the animals were deeply anesthetized with 
sodium pentobarbital, and 1 µl Pontamine sky blue 
was injected via the injection cannula. The perfusion/
fixation was performed intracardially with saline 
followed by 10% formalin/phosphate buffer solution. 
Then, the brains were removed and post­fixed in the 
same fixative. Paraffin sections were prepared and 
stained (hematoxylin + eosin); the location of the 
cannula was verified [26�. Only the animals with 
correct cannula placements were included in the data 
analysis.
 Statistical Analysis. The data were analyzed by 
two­way ANOVA (Factor 1, treatment, and factor 
2, time) followed by the Bonferroni test. One­
way ANOVA followed by Newman­Keuls multiple 
comparisons was used to analyze each independent 
group. P­values below 0.05 (P < 0.05) were considered 
indications of the statistical significance.
RESULTS
Effects of DRN Functional Inactivation on Pain 
Transmission. To determine the effects of the DRN 
on pain modulation, lidocaine was administrated, and 
the tail­flick test was performed 15, 30, 45, and 60 
min after drug administration. The two­way ANOVA 
test indicated that there is a significant difference 
between lidocaine­ and saline­treated groups. The 
Bonferroni post­hoc  test pointed to significant 
differences between lidocaine­ and saline­treated 
groups; dramatic increases in the MPE were obvious 
15 and 30 min after administration but not 45 and 
60 min after it (Fig. 1). One­way ANOVA revealed 
that there were significant increases in the MPE 
in the lidocaine­treated group 15 and 30 but not 
45 and 60 min after administration. No significant 
difference was observed in lidocaine­treated animals 
after administration. We did not see considerable 
alterations of locomotor activity (the differences were 
insignificant). These results indicate that functional 
ablation of the DRN can induce strong analgesia in a 
time­dependent manner.
Effects of DRN Functional Inactivation on 
Morphine Analgesia. Effects of the DRN on pain 
in rats with morphine analgesia were evaluated with 
DRN inactivation via lidocaine administration. The 
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Fig. 1. Effects of reversible inactivation of the dorsal raphe 
nucleus (DRN) on the maximal possible effect (MPE, %) as an 
antinociception index. Lidocaine (2%) was administered for DRN 
inactivation (filled columns), while control­group animals received 
normal saline (open columns). The tail­flick test was performed 
15, 30, 45, and 60 min after drug/saline administration. Means ± 
s.e.m. are shown (n = 8). ** P < 0.01 and *** P < 0.001 indicate 
significant differences from the respective 15­min points before 
administration of lidocaine or saline; † P < 0.05 and ††† P < 0.001 
indicate significant differences from the saline group at the 15­min 
time intervals
Р и с. 1. Впливи оборотної інактивації nucl. raphe dorsalis на 
індекс інтенсивності антиноцицепції (максимальний можливий 
ефект, MPE, %).
MPE (%) was calculated from the data obtained by the 
tail­flick test and analyzed with the two­way and one­
way ANOVA tests.
There were no significant differences between the 
saline­ and lidocaine­treated groups. The MPE values 
did not differ considerably between the two groups 
within the entire test time, while the MPE increased 
significantly after administration in comparison 
with that before administration in both lidocaine­ 
and saline­treated groups (Fig. 2). Modifications 
of locomotor activity were also insignificant. These 
results indicate that functional ablation of the DRN 
exerts no significant effect on the intensity of 
morphine analgesia. 
Effects of DRN Functional Inactivation on 
Morphine Analgesia in Morphine Tolerated Rats. 
To clarify the effects of the DRN on morphine­
tolerated rats, analogous procedures were carried out. 
The control group received saline instead of lidocaine. 
Animals were made tolerant to morphine based on the 
protocol mentioned above. The analyzed data showed 
that the MPE (%) was significantly greater in animals 
treated with lidocaine compared to that in saline­
treated rats within the entire period of observation 
(15 to 60 min after administration). There was also 
a significant difference between the values measured 
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pre­ and post­lidocaine administration within the 
entire time interval. In the control group, there was 
significant difference only at 30 min from the data 
before injection (Fig. 3). Alteration of the locomotor 
activity was not found. These results indicate that 
functional ablation of the DRN strongly facilitates 
morphine analgesia in morphine­tolerant animals.
DISCUSSION
The data obtained in our experiments indicate that: 
(i) transient inactivation of the DRN significantly 
increases the TFL in normal rats; (ii) inactivation of 
the DRN exerts practically no effect on the intensity 
of morphine analgesia; (iii) inactivation of the DRN 
increases the intensity of such analgesia in morphine­
tolerant rats. Our study showed that inactivation of the 
DRN provides significant antinociceptive effects in 
normal rats; in other words, inactivation of the DRN is 
responsible for relative hyperalgesia mediated by pain­
related pathways. The MPE increases significantly 
during DRN inactivation by lidocaine injection; in 45 
min after such injection, the MPE starts to decrease 
because of reduction of the lidocaine effect. 
The LC may mediate the effects of raphe stimulation 
and nociception. This structure contains a considerable 
amount of serotonergic inputs that may originate from 
the DRN [29�; it also contains opioid receptors [30�. 
The LC­mediated excitatory responses to noxious 
stimuli were blocked after DRN electrical stimulation; 
thus, there are, probably, inhibitory serotonergic 
pathways from the DRN to the LC [10�.
There is some evidence demonstrating that the LC 
contains a lot of GABAergic neurons [31,32�. In the 
LC, there is also a significant group of noradrenergic 
cells; this structure is considered a major site of 
localization of noradrenergic cells in the brain [33�. 
It was shown experimentally that serotonin increases 
the GABA release [34�; this is why we suggest that 
serotonergic pathways in the DRN could induce 
intensified GABA release in the LC. In such a 
way, adrenergic cells located in the LC provide an 
inhibitory effect, and this procedure is capable of 
reducing the intensity of pain due to activation of the 
descending inhibitory pain­related system. Therefore, 
serotonin release from the DRN to the LC is limited 
during inactivation of the DRN, and the final effect is 
a decrease in the pain intensity. 
In our study, DRN inactivation exerted no significant 
effect on rats with morphine analgesia; there were no 
significant differences between the saline­treated and 
lidocaine­treated groups. According to some evidence, 
morphine can inhibit GABA release in the LC [35,36�; 
so, adrenergic neurons could decrease pain via this 
mechanism. The target of morphine is a population of 
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Fig. 2. Effects of reversible inactivation of the dorsal raphe nucleus 
(DRN) on the intensity of morphine analgesia. Lidocaine (2%) 
was administered for DRN inactivation, and control­group animals 
received normal saline. Morphine (10 mg/kg, s.c.) was injected 10 
min before the tail­flick test. The latter was performed at 15, 30, 45, 
and 60 min after drug administration. Designations are similar to 
those in Fig. 1. 
Р и с. 2. Впливи оборотної інактивації nucl. raphe dorsalis на 
інтенсивність морфінової аналгезії.
Fig. 3. Effects of reversible inactivation of the dorsal raphe nucleus 
(DRN) on the intensity of morphine analgesia in morphine­tolerated 
rats. Animals received everyday s.c. injections of 20 mg/kg 
morphine (two injections of 10 mg/kg per day) during 4 days 
for induction of morphine tolerance. Tolerant animals received 
applications of lidocaine or saline into the DRN on the test day. On 
this day, 10 mg/kg morphine was injected 10 min before the tail 
flick test. Designations are similar to those in Fig. 1. 
Р и с. 3. Впливи оборотної інактивації nucl. raphe dorsalis на 
інтенсивність морфінової аналгезії у щурів, толерантних щодо 
морфіну.
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GABAergic cells in the LC. This is why the activity of 
DRN neurons would not be affected by morphine [37�. 
Therefore, we can conclude that the serotonin release 
from the DRN could not influence GABA release 
because the morphine level is high enough to block 
this process. There is evidence confirming our results; 
Pan et al. [36� reported that opioids could drive LC 
neurons via presynaptic inhibition of GABAergic 
inputs. Noxious stimuli can excite LC cells, while 
morphine inhibits these units [35, 38�. The lesion of 
noradrenergic LC neurons can intensify inflammatory 
hypersensitivity [39�, which is proof of the analgesic 
role of noradrenergic cells in this mechanism.
In morphine­tolerant rats, analgesic effects were 
observed in the course of transient inactivation of the 
DRN. The differences between the saline­treated and 
lidocaine­treated groups were significant from this 
aspect. Probably, GABA released in the LC wouldn’t 
inhibit anymore by morphine because the tolerance 
was induced. Probably, serotonin released from 
the DRN could display its GABA release­inducing 
properties in the LC of tolerant animals. The reduced 
intensity of analgesia in patients who received repeated 
administration of morphine may be a consequence 
of the development of pharmacological tolerance to 
morphine and tolerance­associated hyperalgesia [16�. 
In our respective experimental group, the analgesic 
effect was preserved for a longer time. It was 
manifested even 45 min after lidocaine administration 
to the DRN. This situation may be related to interaction 
between the opioid and serotonergic systems; there is 
much evidence confirming this conclusion. Activation 
of 5­HT
1A
 receptors could block synthesis and 
release of opioid peptides in the respective spinal 
neuronal systems [11�. Fregoneze et al. [12� showed 
that the opioid and serotonergic systems intensely 
functionally interact with each other in a few parts of 
the brain. Opioid withdrawal behavior decreases due 
to administration of ondansetron, a selective 5­HT
3A 
antagonist [40�. Some papers reported that opioids 
help serotonin­mediated mechanisms to provide 
higher efficacy. For example, Nozaki and Kamei [41� 
declared that serotonin and some selective serotonin 
reuptake inhibitors may show antinociceptive effects, 
and opioids are probably involved in the latter. 
In other studies, it was shown that the analgesic 
effects of serotonergic agonists could be inhbited by 
naloxone (a non­selective opioid receptor antagonist), 
which represents possible involvement of opioids in 
serotonin­induced antinociception [12,42�. Blocking 
of all opioid receptors could abrogate hypotension 
caused by 5­HT
3
 receptor­dependent effects, indicating 
that activation of opioid receptors is required for the 
development of this phenomenon [12�. Therefore, 
we suggest that tolerance to morphine reduces the 
functions of serotonin released from the DRN and 
affecting GABAergic neurons in the LC. This may 
be the reason for prolongation of the analgesic effect 
(45 min after lidocaine administration) in morphine­
tolerant animals.
According to some studies mentioned above, 
serotonin is responsible for analgesic effects, while in 
our study we observed pain­intensifying effects of this 
agent. Further investigations are needed to reveal more 
details of the mechanisms involved in this circuit.
Therefore, we conclude that the DRN plays an 
important role in pain modulation. It influences 
morphine analgesia in morphine­tolerant animals, and 
DRN­born serotonergic projections to the nociceptive 
pathways are responsible for this effect. The neural 
mechanisms of the respective circuits should be 
elucidated in more detail.
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Р е з ю м е
Ми досліджували можливі впливи стану  nucl. raphe dorsa­
lis (DRN) на індуковане морфіном знеболення у щурів, то­
лерантних щодо морфіну. З використанням стереотаксич­
ної техніки лідокаїн (2 %) уводили в DRN, що зумовлювало 
оборотну інактивацію останнього. В день тестування тва­
ринам уводили морфін за 10 хв перед тестом відсмикування 
хвоста (індукції гострого термального болю) та розрахову­
вали максимальний антиноцицептивний ефект   (МАЕ%). У 
групі тварин з толерантністю до морфіну в три послідовні 
доби отримували попередні ін’єкції останнього. В групі з 
ін’єкціями лідокаїну (з інактивацією DRN) значення МАЕ% 
були істотно збільшеними порівняно з контролем. Не спо­
стерігалося, проте, істотних відмінностей між рівнями  ін­
дукованого знеболення в групах тварин, котрим уводили 
фізрозчин та лідокаїн. У той же час антиноцицептивні  від­
повіді на введення морфіну (МАЕ%) у тварин із толерант­
ністю до морфіну були істотнішими у тих щурів, котрим 
уводили лідокаїн, ніж у контрольних. Наші результати доз­
воляють думати, що дефіцит ГАМК у locus coeruleus піс­
ля гальмування вивільнення серотоніну в DRN внаслідок 
функціонального виключення останнього може зумовлюва­
ти аналгезивні ефекти, опосередковані адренергічними клі­
тинами.  
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